Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours
L Hoffmann, G F Persson, L Nygård, T B Nielsen, S Borrisova, F Gaard-Petersen, M Josipovic, A A Khalil, R Kjeldsen, M M Knap, C Kristiansen, D S Møller, W Ottosson, H Sand, R Thing, M Pøhl, T Schytte, L Hoffmann, G F Persson, L Nygård, T B Nielsen, S Borrisova, F Gaard-Petersen, M Josipovic, A A Khalil, R Kjeldsen, M M Knap, C Kristiansen, D S Møller, W Ottosson, H Sand, R Thing, M Pøhl, T Schytte
Abstract
Introduction: SBRT of central lung tumours implies significant risk of toxicity. We are initiating two phase II trials prescribing 56 Gy/eight fractions to PTV, allowing for dose escalation of GTV. We prioritize organs at risk (OAR) constraints over target coverage, making the treatment plans very sensitive to OAR delineation variations. The aim of this study is to quantify the dosimetric impact of contouring variations and to provide a thorough description of pre-trial quality assurance to be used in upcoming trials to provide consistent clinical care.
Materials and methods: Delineation: Seven physicians delineated OAR in three rounds, with evaluations in-between. For each patient case, seven treatment plans, repeatedly using each of the OAR structure sets from the seven physicians, were made and compared to evaluate the dosimetric effect of delineation variability. Treatment planning: Treatment plans for seven cases were made at six departments in two rounds, with discussion in-between.
Results: OAR delineation variation between centres resulted in high variabilities in OAR dose for simulated plans and led to potential overdosage of the lobar bronchus (constraint: D0.03cc < 45 Gy), with maximum doses ranging between 58 Gy (first round), and 50 Gy (third round). For mediastinal tissue, the constraint (D0.03cc < 45 Gy) was violated for the majority of the delineations in all three rounds, with maximum doses of 84 Gy (first round), and 72 Gy (third round).For the treatment planning study, the range of the standard deviation for GTV mean dose was 12.8-18.5 Gy (first round) and 2.8-3.5 Gy (second round).
Conclusions: Even small variations in OAR delineation led to high OAR overdosage. The study demonstrates the importance of having extensive QA procedures in place before initiating clinical trials on dose escalation in SBRT.
Keywords: Central tumours; Lung tumours; Quality assurance; Stereotactic body radiotherapy.
Conflict of interest statement
Conflict of interest statement The authors have no conflicts of interests to report.
Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.
Source: PubMed
Připravované klinické studie
-
Chengdu Zenitar Biomedical Technology Co., LtdZatím nenabírámeObesity With Cardiovascular Risk StudyAustrálie
-
Immuneering CorporationZatím nenabírámeMetastatický nemalobuněčný karcinom plic | Lokálně pokročilý nemalobuněčný karcinom plic | Rakovina plic (NSCLC) | NSCLC (pokročilý nemalobuněčný karcinom plic) | Non-skvamózní nemalobuněčný karcinom plicSpojené státy
-
Florida International UniversityNational Institute of Mental Health (NIMH); Oregon Health and Science UniversityZatím nenabírámeAutismusSpojené státy
-
Envisioning Justice Solutions, IncNáborAgrese | Úzkost | Problémy s hněvem | Depresivní úzkostná porucha | Trauma a poruchy související se stresemSpojené státy
-
Istituto Auxologico ItalianoNáborObezita a nadváha | Obesity / OverweightItálie
-
National Heart, Lung, and Blood Institute (NHLBI)Zatím nenabírámeWaldenstromova makroglobulinémieSpojené státy
-
National Cancer Institute (NCI)Zatím nenabírámeNemalobuněčný karcinom plic | NSCLC | Rakovina plic | Rakovina prostaty | mCRPC | Metastatický karcinom prostaty odolný vůči kastraci | Epiteliální nádory brzlíku | TETs | Thymic Carcinomas | ThymomasSpojené státy
-
National Institutes of Health Clinical Center (CC)Zatím nenabírámeDárci krve | AferézaSpojené státy
-
National Heart, Lung, and Blood Institute (NHLBI)NáborMastné kyseliny, Omega-3 | Rybí olejeSpojené státy
-
National Institute of Dental and Craniofacial Research...Zatím nenabírámeObezita | Obstrukční spánková apnoe (OSA) | Maxilární hypoplazie | Mandibulární hypoplazie | Pediatric Obstructive Sleep Apnea (OSA) | Adeno-Tonsillar Hypertrophy | Intraoral ApplianceSpojené státy
-
National Institute of Mental Health (NIMH)NáborZdravýSpojené státy
-
National Heart, Lung, and Blood Institute (NHLBI)Zatím nenabírámeHypertrofické kardiomyopatie | Left Ventricular Outflow Obstruction | Systolic Anterior MotionSpojené státy